David Bonita

UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients.

Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA.

Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH.

Edwards Lifesciences CardiaQ LLC operates as a medical device company which develops technologies for percutaneous mitral heart valve replacement. The firm focuses on mitral regurgitation which is the most commonly occurring heart valve disease. The company was founded by Arshad Quadri and J. B. Ratz in 2007 and is headquartered in Irvine, CA.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

Imaxio SA develops biopharmaceutical products. It operates as a biotech company which focuses on vaccines, and based on the combination of commercial and research and development activities. The firm provides its services based on proprietary and Agilent DNA chips, notably CGH micro-array analyses. The company was founded by Christian Pradeyrol and Jean Chatellier in 2000 and is headquartered in Lyon, France.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Keystone Heart Ltd. engages in the development and manufacture of cerebral embolic protection devices that aim to reduce the risk of stroke, neurocognitive decline, and dementia caused by brain damage associated with cardiovascular procedures. The company was founded by Dov V. Shimon in 2004 and is headquartered in Caesarea, Israel.

Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland.

Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.

Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada.

Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA.

Cryterion Medical, Inc. operates a medical laboratory that utilizes cryoablation platform. The company was founded on October 11, 2016 and is headquartered in Carlsbad, CA.

Orbimed Private Investments VII seeks investment opportunities in private and public healthcare companies located in globally primarily North America, Asia, Europe and Israel. The fund targets companies operating in the fields of biopharmaceutical, medical device, diagnostics and healthcare services. It provides financing for seed stage capital for large publicly traded companies.

Treeline Biosciences, Inc. develops transformative precision medicines for patients with cancer. The company is based in Stamford, CT. The company was founded by Joshua H. Bilenker. Joshua H. Bilenker has been the CEO since incorporation.